How Peter Marks' FDA departure is impacting pharma, biotech...

2025-03-31 12:37:32 ET More on Beam, CRISPR Therapeutics Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication CRISPR Therapeutics Set To Reach Previous Heights Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy Beam upgraded to Buy at BofA Securities on recent genetic condition treatment Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. Read the full article on Seeking Alpha For further details see: How Peter Marks' FDA departure is impacting pharma, biotech stocks